A theme involving the concentration of management resources in medical and food biotech fields, including genetic medicine and functional food ingredients, using research reagents as the revenue base, while withdrawing from in-house clinical development and contract GMP cell processing services. It covers expansion across multiple biotech business areas, followed by business downsizing and withdrawal.